Drugs / re-activated T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02577588 | May 2016 → Feb 2018 | colorectal carcinoma | National Center for Tumor Diseases, Heidelberg | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | re-activated T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02577588 ↗ |
| Action | Deplete | “tumor antigen specific T cells can recognize and eliminate autologous tumor cells” NCT02577588 ↗ |
| Modality | Cell therapy | “adoptive transfer of ex vivo reactivated p53 specific T cells” NCT02577588 ↗ |